NasdaqGS:ONCE

Stock Analysis Report

Executive Summary

Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases.


Snowflake Analysis

Excellent balance sheet with limited growth.


Similar Companies

Share Price & News

How has Spark Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ONCE has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

3.6%

ONCE

4.2%

US Biotechs

5.3%

US Market


1 Year Return

186.1%

ONCE

1.6%

US Biotechs

-10.7%

US Market

Return vs Industry: ONCE exceeded the US Biotechs industry which returned 10.9% over the past year.

Return vs Market: ONCE exceeded the US Market which returned 24.7% over the past year.


Shareholder returns

ONCEIndustryMarket
7 Day3.6%4.2%5.3%
30 Day2.8%-3.9%-13.6%
90 Day11.8%-5.2%-19.8%
1 Year186.1%186.1%2.4%1.6%-8.9%-10.7%
3 Year141.9%141.9%14.2%11.3%15.5%8.0%
5 Yearn/a-4.1%-8.4%35.2%20.4%

Price Volatility Vs. Market

How volatile is Spark Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Spark Therapeutics undervalued compared to its fair value and its price relative to the market?

12.74x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ONCE's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ONCE's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ONCE is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: ONCE is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ONCE's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ONCE is overvalued based on its PB Ratio (12.7x) compared to the US Biotechs industry average (3.2x).


Next Steps

Future Growth

How is Spark Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?

38.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ONCE is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ONCE is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ONCE is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ONCE's revenue (33.9% per year) is forecast to grow faster than the US market (7.5% per year).

High Growth Revenue: ONCE's revenue (33.9% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ONCE is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Spark Therapeutics performed over the past 5 years?

-27.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ONCE is currently unprofitable.

Growing Profit Margin: ONCE is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ONCE is unprofitable, and losses have increased over the past 5 years at a rate of -27% per year.

Accelerating Growth: Unable to compare ONCE's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ONCE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (103.3%).


Return on Equity

High ROE: ONCE has a negative Return on Equity (-72.38%), as it is currently unprofitable.


Next Steps

Financial Health

How is Spark Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: ONCE's short term assets ($467.9M) exceed its short term liabilities ($100.3M).

Long Term Liabilities: ONCE's short term assets ($467.9M) exceed its long term liabilities ($257.2M).


Debt to Equity History and Analysis

Debt Level: ONCE's debt to equity ratio (14.2%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if ONCE's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: ONCE has a high level of physical assets or inventory.

Debt Coverage by Assets: ONCE's debt is covered by short term assets (assets are 9.5x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ONCE has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: ONCE has sufficient cash runway for 2.4 years if free cash flow continues to grow at historical rates of 3.7% each year.


Next Steps

Dividend

What is Spark Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ONCE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate ONCE's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ONCE's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ONCE's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ONCE's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.3yrs

Average management tenure


CEO

Jeff Marrazzo (40yo)

6.58s

Tenure

US$3,598,572

Compensation

Mr. Jeffrey D. Marrazzo, also known as Jeff, M.B.A., M.P.A. is a Co-Founder of Spark Therapeutics, Inc. (a/k/a, Spark Therapeutics, LLC) and has been its Chief Executive Officer since May 2013. Mr. Marrazz ...


CEO Compensation Analysis

Compensation vs Market: Jeff's total compensation ($USD3.60M) is about average for companies of similar size in the US market ($USD4.99M).

Compensation vs Earnings: Jeff's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Jeffrey Marrazzo
Co-Founder6.58yrsUS$3.60m0.92% $40.7m
Katherine High
Co-Founder5.25yrsUS$2.28m0.72% $31.9m
Stephen Webster
Chief Financial Officer5.42yrsUS$2.05m0.016% $698.6k
Daniel Faga
Chief Business Officer3.58yrsUS$2.55m0.10% $4.4m
J. Wright
Scientific Co-Founderno datano datano data
Jean Bennett
Scientific Co-Founder and Advisorno datano datano data
Beverly Davidson
Scientific Co-Founder and Advisorno datano datano data
Federico Mingozzi
Chief Scientific Officer2.25yrsno data0.033% $1.4m
Ryan Asay
Head of Investor Relationsno datano datano data
Joseph La Barge
Chief Legal Officer & Secretary5.92yrsUS$2.00m0.13% $5.8m

5.3yrs

Average Tenure

48yo

Average Age

Experienced Management: ONCE's management team is seasoned and experienced (5.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Jeffrey Marrazzo
Co-Founder6.58yrsUS$3.60m0.92% $40.7m
Katherine High
Co-Founder5.25yrsUS$2.28m0.72% $31.9m
Vincent Milano
Independent Director5.5yrsUS$387.89k0.0078% $343.6k
Lota Zoth
Independent Director3.92yrsUS$399.47k0.0078% $343.6k
Lars Ekman
Independent Director5.58yrsUS$397.89k0.0078% $343.6k
Charles Sigal
Independent Director5.92yrsUS$388.20k0.037% $1.6m
Robert Perez
Independent Director1.92yrsUS$845.74k0.0065% $286.2k
Anand Mehra
Independent Director5.58yrsUS$379.11kno data
Steven Altschuler
Chairman6.17yrsUS$424.17k0.073% $3.2m

5.6yrs

Average Tenure

59yo

Average Age

Experienced Board: ONCE's board of directors are considered experienced (5.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.9%.


Top Shareholders

Company Information

Spark Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Spark Therapeutics, Inc.
  • Ticker: ONCE
  • Exchange: NasdaqGS
  • Founded: 2013
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$4.410b
  • Shares outstanding: 38.52m
  • Website: https://www.sparktx.com

Number of Employees


Location

  • Spark Therapeutics, Inc.
  • 3737 Market Street
  • Suite 1300
  • Philadelphia
  • Pennsylvania
  • 19104
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ONCENasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDJan 2015
272DB (Deutsche Boerse AG)YesCommon StockDEEURJan 2015
0L8LLSE (London Stock Exchange)YesCommon StockGBUSDJan 2015

Biography

Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec) for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy and viable retinal cells. The company’s gene therapy product candidates comprise SPK-8011 and SPK-8016 for hemophilia; SPK-7001 for choroideremia; and SPK-9001 for hemophilia B. It is also developing other liver-directed gene therapies, including SPK-3006 for Pompe disease; and neurodegenerative disease product candidates to address Huntington's disease and others, as well as TPP1 deficiency, which is a form of Batten disease. The company’s preclinical programs targets inherited retinal diseases, including Stargardt's disease. The company has collaboration agreement with Pfizer, Inc. for the development and commercialization of SPK-FIX product candidates in its gene therapy program for the treatment of hemophilia B. It also has licensing and commercialization agreement with Novartis to develop and commercialize voretigene neparvovec outside the United States. Spark Therapeutics, Inc. was founded in 2013 and is headquartered in Philadelphia, Pennsylvania. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/12/19 00:40
End of Day Share Price2019/12/17 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.